BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 27510662)

  • 21. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?
    Nakamura H; Murakami R; Hirai T; Kitajima M; Yamashita Y
    Acta Radiol; 2013 Mar; 54(2):214-20. PubMed ID: 23138021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological markers and prognosis in recurrent oral cancer after salvage surgery.
    Agra IM; Carvalho AL; Pinto CA; Martins EP; Filho JG; Soares FA; Kowalski LP
    Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):743-9. PubMed ID: 18645125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer.
    Lian PL; Liu Z; Yang GY; Zhao R; Zhang ZY; Chen YG; Zhuang ZN; Xu KS
    World J Gastroenterol; 2016 Apr; 22(14):3852-9. PubMed ID: 27076771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
    Mangla R; Singh G; Ziegelitz D; Milano MT; Korones DN; Zhong J; Ekholm SE
    Radiology; 2010 Aug; 256(2):575-84. PubMed ID: 20529987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors.
    Nakagawa T; Kubota T; Kabuto M; Sato K; Kawano H; Hayakawa T; Okada Y
    J Neurosurg; 1994 Jul; 81(1):69-77. PubMed ID: 8207529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.
    Pelloski CE; Lin E; Zhang L; Yung WK; Colman H; Liu JL; Woo SY; Heimberger AB; Suki D; Prados M; Chang S; Barker FG; Fuller GN; Aldape KD
    Clin Cancer Res; 2006 Jul; 12(13):3935-41. PubMed ID: 16818690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive Factors Determining the Overall Outcome of Primary Spinal Glioblastoma Multiforme: An Integrative Survival Analysis.
    Konar SK; Maiti TK; Bir SC; Kalakoti P; Bollam P; Nanda A
    World Neurosurg; 2016 Feb; 86():341-8.e1-3. PubMed ID: 26348566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
    Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
    BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Significance of Epidermal Growth Factor Receptor in Patients of Glioblastoma Multiforme.
    Tripathy K; Das B; Singh AK; Misra A; Misra S; Misra SS
    J Clin Diagn Res; 2017 Aug; 11(8):EC05-EC08. PubMed ID: 28969132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
    Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
    Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome and prognostic factors in adult cerebellar glioblastoma.
    Babu R; Sharma R; Karikari IO; Owens TR; Friedman AH; Adamson C
    J Clin Neurosci; 2013 Aug; 20(8):1117-21. PubMed ID: 23706183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
    Noël G; Quetin P; Heymann S; Karamanoukian D; Schott R
    Cancer Radiother; 2009 Jan; 13(1):17-23. PubMed ID: 19091619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.
    Sminia P; Stoter TR; van der Valk P; Elkhuizen PH; Tadema TM; Kuipers GK; Vandertop WP; Lafleur MV; Slotman BJ
    J Cancer Res Clin Oncol; 2005 Oct; 131(10):653-61. PubMed ID: 16133570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression of the phosphatase regenerating liver 3 gene is associated with outcome in patients with colorectal cancer.
    Tamagawa H; Oshima T; Yoshihara K; Watanabe T; Numata M; Yamamoto N; Tuschida K; Shiozawa M; Morinaga S; Akaike M; Masuda M; lmada T
    Hepatogastroenterology; 2012 Oct; 59(119):2122-6. PubMed ID: 22440248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy.
    Smid EJ; Stoter TR; Bloemena E; Lafleur MV; Leemans CR; van der Waal I; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1323-9. PubMed ID: 16750322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
    Cox G; Jones JL; O'Byrne KJ
    Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines.
    Amoureux MC; Coulibaly B; Chinot O; Loundou A; Metellus P; Rougon G; Figarella-Branger D
    BMC Cancer; 2010 Mar; 10():91. PubMed ID: 20219118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
    Montgomery RM; Queiroz Lde S; Rogerio F
    Arq Neuropsiquiatr; 2015 Jul; 73(7):561-8. PubMed ID: 26200049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
    Pelloski CE; Ballman KV; Furth AF; Zhang L; Lin E; Sulman EP; Bhat K; McDonald JM; Yung WK; Colman H; Woo SY; Heimberger AB; Suki D; Prados MD; Chang SM; Barker FG; Buckner JC; James CD; Aldape K
    J Clin Oncol; 2007 Jun; 25(16):2288-94. PubMed ID: 17538175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.